Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s innovative pipeline of personalised cancer therapies.The company is developing customised approaches to treating cancer including targeted and cellular therapies.
Mr Yatomi-Clarke describes Prescient as a compelling investment case which is well-funded to deliver value-adding milestones across its various cancer treatments.
Watch to the full interview below.